The time course and magnitude of allopurinol effect on serum uric acid in patients with gout

Can a better understanding of time course and magnitude of allopurinol effect on serum uric acid provide the basis for a revised dosing strategy whcih will enable more patients to acheive the clinical target for serum uric acid of < 0.36 mmol/L?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12613000114741

Enrollment

Registered

2013-01-31

Start date

2013-03-01

Completion date

2014-04-28

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Allopurinol is used to treat gout and works by reducing serum urate concentrations. Current prescribing guidelines frequently result in a suboptimal reduction in urate. This project aims to quantify the time course and magnitude of allopurinol effect on serum urate at the initiation of therapy in relation to plasma drug concentrations and dose. Serum urate and plasma drug concentrations will be measured and used to develop a model that will allow us to predict the probability of successful urate lowering under different dosing regimens. This model will be used to develop a revised dosing strategy in future research.

Interventions

This is an observational study in patients who are initiating allopurinol for the treatment of gout. Blood sample for the measurement of allopurinol, oxypurinol and uric acid concentrations will be collected on Days 1,2,3,7,14,21 and 28. Patients will be observed for 28 days.

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

Patients with gout as defined by the American College of Rheumatology Criteria who are initiating allopurinol as part of routine clinical care.

Exclusion criteria

1. Patients who are unable or unwilling to give written informed consent 2. Patients taking concurrent losartan, diuretics or uricosuric agents.

Outcome results